|
| |
Agilent Technologies Expands miRNA Microarray Catalogue with New Human,
Mouse and Rat Assays
SSANTA CLARA, Calif., April 10, 2008 -- Agilent Technologies Inc. (NYSE: A)
today introduced three new microRNA microarray designs: Human miRNA Microarray
v2.0, Mouse miRNA Microarray v1.0 and Rat miRNA Microarray v1.0. All are based
on the Sanger Institute’s miRBase 10.1, updated in December 2007.
“Researchers tell us that they value specificity and sensitivity above other
attributes, and this plays well to Agilent’s strengths in microarray
manufacturing,” said Yvonne Linney, Agilent vice president and general manager,
Genomics. “Our breakthrough direct-labeling method requires very small amounts
of sample input, and the flexibility of our SurePrint inkjet fabrication
platform makes it extremely easy to update content as it becomes available.”
The updated Human miRNA Microarray v2.0 contains 723 human and 76 human viral
probe sets. Viral miRNAs are increasingly associated with some cancers, so
Agilent included these probe sets to provide additional value for cancer
researchers.
The new Mouse miRNA Microarray v1.0 contains all known mouse and mouse gamma
herpes virus miRNAs. There are 567 mouse and 10 mouse gamma herpes virus
distinct probe sets.
The new Rat miRNA Microarray v1.0 contains all 350 known rat miRNA probe sets.
Agilent launched the first comprehensive microarray system for expression
profiling of human miRNAs in April 2007, and it has been positively received by
the research community.
“Tumor-specific predictors based on high-throughput nucleic acid assays offer
significant advances over current clinically -derived models,” said David Neil
Hayes, M.D., assistant professor of medicine, Division of Hematology/Oncology,
University of North Carolina School of Medicine. The Hayes team is studying
glioblastoma, a highly aggressive type of brain tumor. “My team is on the cusp
of being able to correlate a tumor’s genetic pattern to clinically -relevant
events. We would be hard-pressed to reach this ability in such a short period of
time to elucidate a tumor’s genetic pattern and understand the regulatory
networks between miRNA and gene expression, without the use of Agilent’s miRNA
and gene expression arrays.”
The Agilent miRNA microarray platform’s limit of detection is less than 1
attomole with a dynamic range of five orders of magnitude. Probe specificity and
the unique labeling procedure discriminates individual miRNAs. Agilent’s novel
method for efficiently labeling miRNA in total RNA eliminates tedious size
fractionation and requires only 100 nanograms of input RNA from precious
samples.
The Agilent miRNA assays are delivered as eight 15K arrays per standard 1 in. x
3 in. glass slide. The Human v2.0 kit, Mouse v1.0 kit and Rat v1.0 kit are each
available as two different pack sizes: one slide with eight arrays or three
slides with 24 arrays. The human, mouse and rat miRNA assays are also available
as individual slides, each containing eight microarrays. This helps users tailor
purchases to their research requirements.
For more information about Agilent’s upgraded miRNA portfolio, please visit
www.opengenomics.com .
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is the world’s premier measurement company
and a technology leader in communications, electronics, life sciences and
chemical analysis. The company’s 19,000 employees serve customers in more than
110 countries. Agilent had net revenue of $5.4 billion in fiscal year 2007.
Information about Agilent is available on the Web at
www.agilent.com .
# # #
NOTE TO EDITORS: Further technology, corporate citizenship and executive news is
available on the Agilent news site at
www.agilent.com/go/news .
Press release URL:
http://www.agilent.com/about/newsroom/presrel/2008/09apr-ca08024.html
Additional metadata keywords (for Web use only): genomics, cancer research
EDITORIAL CONTACTS:
Claudia Hachtel, Agilent Technologies
Nicki Muir, Alto Marketing
+49-7243-602 100
+44-1489-55 76 72
claudia_hachtel@agilent.com
nickim@alto-marketing.com
Sarah Perceval, Alto Marketing
+44-1489-55 76 72
sarahp@alto-marketing.com
| |
|
